shortage of glp-1 receptor agonists The agonist shortage: What you need to know and do GLP-1 No Longer on FDA's
Description
In general, the majority of studies suggest that the risk of side effects with DPP-4 inhibitors is equivalent to that of a placebo (inactive pill) [14]

We used R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria) along with the packages metafor and meta to carry out the analyses

So Can You Take a GLP1 and Breastfeed

Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH

It is noteworthy that this superior effectiveness extended to primates (humans and cynomolgus monkeys) and rodent models of obesity and diabetes, such as db/db (diabetic) mice and Zucker diabetic fatty (ZDF) rat
